Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Synovial Sarcoma - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 77 | Code: MRS - 18145


Global Markets Directs, Synovial Sarcoma Pipeline Review, H1 2015, provides an overview of the Synovial Sarcomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Synovial Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Synovial Sarcoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Synovial Sarcoma and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Synovial Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Synovial Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2

List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Synovial Sarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Synovial Sarcoma - Overview 7
Pipeline Products for Synovial Sarcoma - Comparative Analysis 8
Synovial Sarcoma - Therapeutics under Development by Companies 9
Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 10
Synovial Sarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Synovial Sarcoma - Products under Development by Companies 14
Synovial Sarcoma - Products under Investigation by Universities/Institutes 15
Synovial Sarcoma - Companies Involved in Therapeutics Development 16
Adaptimmune Limited 16
Eisai Co., Ltd. 17
Karyopharm Therapeutics, Inc. 18
Merck & Co., Inc. 19
Novartis AG 20
OncoTherapy Science, Inc. 21
Synovial Sarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
E-7438 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
everolimus - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OTSA-101 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pembrolizumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
selinexor - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SSTC-104 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Synovial Sarcoma - Recent Pipeline Updates 51
Synovial Sarcoma - Discontinued Products 72
Synovial Sarcoma - Product Development Milestones 73
Featured News & Press Releases 73
Oct 17, 2014: Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells Targeting Synovial Sarcoma 73
Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US 75
Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 75

Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Synovial Sarcoma, H1 2015 7
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Synovial Sarcoma - Pipeline by Adaptimmune Limited, H1 2015 16
Synovial Sarcoma - Pipeline by Eisai Co., Ltd., H1 2015 17
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 18
Synovial Sarcoma - Pipeline by Merck & Co., Inc., H1 2015 19
Synovial Sarcoma - Pipeline by Novartis AG, H1 2015 20
Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Synovial Sarcoma Therapeutics - Recent Pipeline Updates, H1 2015 51
Synovial Sarcoma - Discontinued Products, H1 2015 72

List of Figures

Number of Products under Development for Synovial Sarcoma, H1 2015 7
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing